News flow

We were told in April that Noxopharm proposed to list on Nasdaq; and today we were told that Nyrada planned to list (on the ASX?) 1n 2019 and Nasdaq in 2020.

It seems to me that the next few months will necessarily include a flurry of reports designed to educate potential investors. For instance, I expect:

1. A Nyrada prospectus that sets out the scientific and investment case. The four Nyrada drugs each have blockbuster potential and should be partnership candidates for big pharma once proof-of-concept has been established in the clinic. This would provide an early return-on-investment for Noxopharm shareholders, who own a significant chunk of Nyrada.

2. We can expect a Noxopharm newsletter which summarises key developments and looks into the future. The last one was published in September 2018.

3. DARRT 1200 mg interim results should be due in August. This will show whether responses are dose-related; and the updated results from earlier treatments will indicate whether responses are durable - even without further treatment..

4. LuPIN 800 mg interim results should be of great interest. The first 16 patients experienced a dose-related response, but it was eye-opening to learn that the PSA of the first 400mg patient continued to decline one year after treatment ended.

5. A Noxopharm prospectus will be published ahead of its proposed Nasdaq listing. Australian speculators worry about timelines; US investors are more concerned with results, the scientific case, and the potential of Veyonda to activate STING and induce abscopal responses. It makes sense to list in the US if you have an attractive product.

6. I hope to learn more about Noxopharm Patent Applications not yet in the public domain.

7. Nyrada has submitted a number of Patent Applications that are not yet in the public domain. An outline of these in the prospectus will provide more manna from heaven.

8. If any of the three Patent Applications currently cleared for examination by the USPTO are approved, this would be significant news.

9. It will be fascinating to learn whether there are any patentable discoveries about the way in which Veyonda activates STING. This would be bigger than Ben Hur.